Bayer S.A./NV

Novartis: - A Detailed And Comprehensive Overview Of Current Financial Position, Company Strategy, Product And Pipeline Analysis.
M2 Presswire; 12/3/2009; 1396 words; ...review of the company's activities together with...products. The company's financial performance is...review of the company's product portfolio and research...Harvard University - Bayer Schering Pharma - Biovail...Pharmaceuticals - Galapagos NV - Genelabs Technologies...

European Stocks bounce at the Closing Session.
ecPulse; 11/25/2009; 802 words; ...Wednesday after the better than expected U.S. housing, confidence, and spending data...looking at the index shed points due to EADS NV share as it plummeted 3.80% to e1/412...looking at the index shed points due to Bayer share as it plummeted 0.88% to e1/453...

ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours.
PR Newswire; 11/16/2009; 1568 words; ...FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and...Therapeutics in Boston, U.S. TB-403 was well tolerated...disease and cancer. The Company's lead product microplasmin is...partners, such as ALK-Abello, Bayer HealthCare, ImmunoGen, Mitsubishi...

Other News To Note.
BIOWORLD Today; 11/4/2009; 1988 words; ...in September. RSD1235's mechanism of action involves...exclusive license in the U.S. (including Puerto Rico...manufacture and market DepoMed's Metformin GR. The agreement...Galapagos Genomics NV, of Mechelen, Belgium...genomics collaboration with Bayer AG, of Leverkusen, Germany...

Dyax Raising $38.5 Million To Fund Its DX-88 Trials.
BIOWORLD Today; 11/3/2009; 1162 words; ...with the decision. Dyax's shares (NASDAQ:DYAX...transfusion requirements. Dyax's two target indications...Behring, Pharming Group NV and Jerini AG in partnership...the surgery indication, Bayer AG markets a plasma kallikrein...house using the company's phage display technology...